Core Insights - The document contains regulated information that is essential for stakeholders and investors to understand the company's current status and future outlook [1] Group 1 - The company has released a communiqué that is intended for publication, indicating a significant update or announcement [1] - The attachment referenced may contain detailed financial data or operational insights relevant to investors [1]

Core Insights - The company reported a slight decline in sales for FY 2025, with total sales of €27,283 million, down 0.3% year-over-year, but like-for-like (LFL) sales grew by 4.5% driven by positive volume/mix and pricing strategies [2][9][10] - Recurring operating income increased by 3.0% to €3,665 million, with a recurring operating margin improvement of 44 basis points to 13.4% [2][19] - The company generated strong free cash flow of €2,799 million, although this was a decrease of 6.8% compared to the previous year [2][21] Financial Performance - FY 2025 sales were €27,283 million, with LFL sales growth of 4.5%, attributed to a 2.7% increase in volume/mix and a 1.8% increase in price [5][9] - Recurring net income attributable to the Group increased by 5.0% to €2,461 million, while total net income decreased by 9.7% to €1,825 million due to non-recurring expenses [2][20] - Recurring diluted EPS rose by 4.6% to €3.80, while reported EPS fell by 10.1% to €2.82 [2][20] Operational Highlights - The company experienced strong sales momentum across all categories and geographies, particularly in China, North Asia & Oceania, and Europe [4][5] - Q4 2025 sales were €6,684 million, reflecting a 4.7% increase LFL, driven by strong volume/mix and pricing [8][10] - The company proposed a dividend of €2.25 per share, up 4.7% from the previous year, reflecting confidence in future performance [23] Strategic Initiatives - The company is focused on reshaping its portfolio, enhancing capabilities in U.S. Medical Nutrition, and advancing microbiome science and digitalization [6][4] - The 2026 guidance aligns with mid-term ambitions, expecting LFL sales growth between 3% and 5%, with recurring operating income anticipated to grow faster than sales [26][7] - The company has been recognized for its sustainability efforts, achieving CDP 'Triple A' List and B Corp certification [5][32]

Core Insights - The company achieved a like-for-like sales growth of +4.5% in FY 2025, driven by positive volume/mix and pricing strategies [6][9][19] - Recurring operating income increased by +3.0% to €3,665 million, with a recurring operating margin of 13.4%, up +44 basis points from the previous year [2][19] - The company reported a net income of €1,825 million, a decrease of -9.7% compared to FY 2024, primarily due to non-recurring expenses [2][21] Financial Performance - FY 2025 sales were €27,283 million, reflecting a -0.3% change on a reported basis, while like-for-like sales grew by +4.5% [2][9] - Recurring net income attributable to the Group increased by +5.0% to €2,461 million, with recurring diluted EPS rising by +4.6% to €3.80 [2][20] - Free cash flow decreased by -6.8% to €2,799 million, with cash flow from operating activities at €3,779 million, down -1.3% [2][21] Operational Highlights - Strong sales growth was observed across all categories and geographies, particularly in China, North Asia & Oceania, and Europe [4][12][14] - The company continued to invest in capabilities, science, and innovation while maintaining a focus on sustainability, achieving CDP 'Triple A' List recognition and B Corp certification [4][31] - The proposed dividend for FY 2025 is €2.25 per share, representing a +4.7% increase from the previous year [22] Strategic Initiatives - The company is advancing its "Renew Danone" strategy, focusing on scaling U.S. Medical Nutrition, enhancing dairy operations, and accelerating digitalization [5][31] - Guidance for 2026 indicates expected like-for-like sales growth between +3% and +5%, with recurring operating income anticipated to grow faster than sales [25][31] - The company is actively reshaping its portfolio and addressing areas requiring further progress, particularly in North America [5][11]

Core Viewpoint - The company has reported a strong start to 2025 with a like-for-like (LFL) sales growth of +4.3%, indicating the effectiveness of its health-oriented portfolio and execution strategy [3][4]. Group 1: First Quarter Sales Performance - Total sales for Q1 2025 reached €6,844 million, reflecting a +4.3% increase on a like-for-like basis, driven by a +1.9% increase in volume/mix and a +2.4% increase in price [4]. - Reported sales increased by +0.8%, impacted negatively by a scope change of -3.0% due to the sale of Horizon Organic and Wallaby, and a forex impact of -0.8% [4][5]. - The company experienced broad-based growth across all categories, with particularly strong performance in China, North Asia & Oceania, and solid growth in North America and Europe [4][6][7][8]. Group 2: Sales by Geography - In Europe, LFL sales grew by +2.0%, supported by a +1.9% increase in volume/mix, achieving positive growth momentum for six consecutive quarters [6]. - North America saw LFL sales increase by +3.7%, driven by strong performance in High Protein products and Medical Nutrition [7]. - China, North Asia & Oceania reported LFL sales growth of +9.9%, with significant contributions from Specialized Nutrition and Waters [8]. - Latin America experienced LFL sales growth of +9.0%, primarily led by the Aptamil brand in Specialized Nutrition [9]. - The Rest of the World had LFL sales growth of +3.3%, with notable performance in EDP and Specialized Nutrition [10]. Group 3: 2025 Guidance and Recent Developments - The company has confirmed its 2025 guidance, expecting LFL sales growth between +3% and +5%, with recurring operating income anticipated to grow faster than sales [12]. - Recent developments include a completed share buyback of €192 million and a successful bond issuance of €800 million, reflecting strong investor confidence in the company's business model [13][14].